In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers

Area of Science:

• Neuroscience
• Molecular Genetics
• Radiochemistry

Background:

• Investigated dopaminergic and serotonergic terminal density in individuals with DCTN1 gene mutations.
• Focused on two clinically affected subjects with Perry syndrome.

Purpose of the Study:

• To assess dopaminergic and serotonergic terminal density using Positron Emission Tomography (PET).
• To evaluate the impact of DCTN1 gene mutations on neurotransmitter systems.

Main Methods:

• Utilized PET imaging with tracers for dopamine synthesis (FDOPA), vesicular monoamine transporter 2 (DTBZ), dopamine D2/D3 receptors (RAC), and serotonin transporter (DASB).
• Examined three subjects with DCTN1 mutations, including two with Perry syndrome.

Main Results:

• FDOPA-PET and DTBZ-PET showed reduced striatal uptake, indicating dopaminergic deficits.
• RAC-PET revealed increased uptake in affected striatal areas.
• DASB-PET demonstrated significant changes in serotonin transporter uptake across multiple cortical and subcortical regions.

Conclusions:

• The study provides evidence for both striatal dopaminergic and widespread cortical/subcortical serotonergic dysfunctions in individuals with DCTN1 gene mutations.
• Findings suggest a dual neurotransmitter system involvement in the pathophysiology associated with DCTN1 mutations.